Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results